

The Treatment of Metastatic Prostate Cancer Using Hormonal Therapy: A narrative review

ABSTRACT

The incidence of prostate cancer in men has increased significantly, making it one of the most prevalent malignancies in the male population. Over the past two decades, there has been a substantial shift in the approach to managing metastatic prostate cancer, with the approval of novel medications resulting from multiple pivotal phase III trials. These medications offer a range of therapeutic alternatives to patients, with varying modes of action. Despite the progress made in prostate cancer treatment, early metastases and drug resistance continue to pose significant challenges. In this narrative review, we examined the evidence regarding the effectiveness of hormone therapy in the treatment of metastatic prostate cancer, drawing on data from important clinical trials of hormonal therapy. In addition, we conducted a search of ClinicalTrials.gov to identify ongoing and upcoming trials related to metastatic and resistant prostate cancer. Finally, we present an overview of the pathophysiology of these residual effects and review relevant translational research and observational cohort studies.

KEYWORDS: Metastatic prostate cancer; Castration-resistant prostate cancer; Androgen deprivation; Hormonal therapy

INTRODUCTION

Between the bladder and the penis lies the prostate, an accessory gland of the male reproductive system. Prostate cancer (PC) is the most prevalent form of cancer among men in many parts of the world. It is the second most common malignancy in older men and accounts for over 80% of cases in individuals above 65 years of age; however, only 10% of these cases result in mortality [1]. Annually, an estimated 1.6 million men are diagnosed with prostate cancer, and 366,000 succumb to the disease. Incidences of prostate cancer are more frequently reported in affluent nations than in developing countries. In 2016, prostate cancer was the leading cause of all incidental cancers in the United States, with an estimated 180,890 patients affected [2].

The process of aging constitutes a notable risk factor for the development of prostate cancer, with a higher likelihood observed in individuals who exhibit a positive genetic predisposition. The risk of developing prostate cancer is found to be 2 to 3 times greater in those with a familial history of the disease in comparison to those without such history. The utility of genetic markers has been demonstrated in enhancing the diagnostic potential for prostate cancer, particularly in identifying high-risk tumors, thus aiding in the

screening and treatment process. Furthermore, obesity and a high-fat diet have been shown to contribute to the growth and progression of prostate cancer, with foods high in fat, such as grilled or barbecued red meat, significantly increasing the risk of disease [1,2].

On the other hand, individuals with a low risk of prostate cancer may develop tumors that produce minimal discomfort, which may not necessitate intervention. In addition, studies have identified a correlation between race and increased susceptibility to prostate cancer, with black men having a greater likelihood of developing the disease compared to white men. Late detection, genetic variations, environmental factors, and socioeconomic status are also factors that have been implicated in the onset and progression of prostate cancer [2].

Metastasis is known to cause a rapid advancement in prostate cancer cases. Recent studies indicate that men shorter than 5 feet 6 inches are less susceptible to aggressive forms of prostate cancer compared to their taller counterparts. While hormone therapy can effectively suppress the growth of hormone-dependent tumors, the standard treatment for prostate cancer still heavily relies on surgical and radiological interventions for patients who are unsuitable for those procedures [3]. Unfortunately, hormone-independent prostate cancer can emerge and cause complications, leading to metastasis and recurrence. Hormones such as luteinizing hormone-releasing hormone (LHRH) and androgens like testosterone and dihydrotestosterone fuel the growth of prostate cancer [3,4]. In this paper, we discuss the significance of hormone therapy as a treatment option for prostate cancer, including the strategies that prostate cancer employs to resist hormone therapy, ultimately leading to castration resistance. We also highlight the latest studies that seek to advance the field of hormone therapy for the treatment of prostate cancer.

MECHANISM OF PROSTATE CANCER DEVELOPMENT (GENE MUTATION)

A gene mutation, which may be hereditary or acquired, is the genetic etiology of the disease cancer. Compared to breast cancer (1.2 per Mb) and colorectal cancer (3.1 per Mb), non-metastatic prostate cancer has a lower average mutation rate of 0.7 mutations per megabase (Mb). A higher amount of genomic instability and chromosomal rearrangements can also be linked to prostate cancer. Single nucleotide variants cause prostate cancer with a few insertions, deletions, rearrangements, abnormal methylation patterns, or changes in the number of gene copies [4]. Exome sequencing research was carried out on 50 autopsies of castration-resistant prostate cancer that had already received treatment in Grasso's analysis. Nine genes, including TP53, ZFH3, AR, RB1, PTEN, CDK12, APC, MLL2, and OR5L1, were found to frequently exhibit mutations. The data ensemble reveals that the aberrations in androgen receptors (AR) and their associated proteins, such as protein remodelers and the ETS genes referred to be AR co-regulators, are frequently changed or mutated in prostate cancer [5]. However, about 12 genes were frequently mutated in primary prostate cancer study, which examined 112 primary tumors with a median of 30 non-synonymous single nucleotide variants. These genes included TP53, PTEN, PIK3CA, SPOP, FOXA1, MED12,

CDKN1B, ZNF595, THSD7B, NIPA2, C14 or F49, and SCN11A. In the androgen-signaling pathway, a few of these genes have significant roles. The CDH1 gene encodes a chromatin remodeling enzyme that requires Adenosine Triphosphate (ATP). Research has demonstrated that the level of its deletion rises in proportion to the tumor grade and is more common in ERG fusion-negative cancer than fusion-positive cancer [6].

The functional investigation demonstrates the significance and necessity of CDH1 expression for effectively recruiting AR at various responsive gene promoters, which accounts for why CDH1 deletion limits the creation or generation of ERG rearrangement [5,6]. The metabolism of dehydroepiandrosterone (DHEA) is accelerated by the transformation of growth factor b1 (TGF-b1) into androgens and prostate-specific antigens. Both stromal and epithelial (LAPC-4) cells are grown concurrently in this prostate tissue type. Red clover isoflavones block the effects of transforming growth factor b on androgenicity, and the mechanisms governing and regulating these processes are investigated. The three hydroxysteroid dehydrogenases involved in the conversion of DHEA to testosterone, 3b-HSD, HSD-17b1, and HSD-17b5 were investigated. To TGF-b1/DHEA-induced PSA in LAPC-4 co-culture, individual HSD depletion in 6S cells is reduced [8]. A million people have died from this disease due to late discovery, lack of access to appropriate care, and the requirement for a viable treatment method [7].

FIRST-LINE PROSTATE CANCER HORMONAL TREATMENT (CASTRATION/HORMONAL THERAPY)

When it comes to how testosterone deprivation and the ensuing testosterone therapy affect the development of prostate cancer, this has historically been a disputed topic. This concept has its roots in the research of Kutscher and Wolbergs, who found that the prostates of humans and monkeys contain a sizable quantity of acid phosphatase [8]. Huggins and Hodges concluded in 1945 that giving testosterone (an androgen) to men with testosterone deficiency would cause prostate cancer. With the skeptical view that androgen removal prevents the progression of prostate cancer to metastatic prostate cancer resulted in the development of androgen deprivation therapy (ADT) [9]. According to several studies conducted over the past ten years, men receiving testosterone therapy, those with high testosterone levels, or those who underwent a prostatectomy after receiving exogenous testosterone do not run a higher risk of developing advanced stages of prostate cancer [7,9].

The Saturation Model was introduced by Morgentaler and Traish in 2009 and postulated that androgen receptors, a ligand-dependent transcription factor, control the onset and progression of prostate cancer, with testosterone having a maximum effect on the tumor's growth [9]. The saturation model is still the subject of some contention, albeit [9,10]. Studies have indicated that the development and spread of PC cancer are aided by AR signaling pathways. Nevertheless, ADT can inhibit PC growth and metastasis and produce a reduction or loss of androgen receptors (AR) [11].

As the first-line treatment for metastatic prostate cancer, ADT can be administered via surgical bilateral orchiectomy or via medical castration using antiandrogens, luteinizing hormone-releasing hormone (LHRH) agonists, or luteinizing hormone-releasing hormone antagonists (LHRHA), either in combination or individually [12]. Diethylstilbestrol (DES) was initially employed to accomplish androgen deprivation, despite having a markedly increased cardiovascular mortality rate. However, it has been demonstrated that they can lessen cardiovascular toxicity when used in small dosages. Furthermore, the hypothalamic-pituitary-gonadal axis is affected negatively by DES, which lowers LH secretion and, in turn, lowers androgen production [11,12]. Therefore, ADT's main objectives in treating advanced prostate cancer were to increase castrate testosterone levels while reducing cardiovascular damage. Lei and Liu concluded that complete radical prostatectomy (RP) or radiation therapy (RT) with ADT could both be used as the first-line therapy for high-risk prostate cancer while also taking into account the individual's phenotypic and genotypic characteristics through a systemic review and meta-analysis of the survival outcome of first-line treatment options [12].

LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) AGONIST

GnRH is a decapeptide produced by the hypothalamus that regulates serum testosterone levels by stimulating the anterior pituitary gland to release Luteinizing Hormone. A concomitant reduction in LH secretion is seen when the Luteinizing Hormone Releasing Hormone (LHRH) agonist treatment scheme is initiated via the downregulation of LHRH receptors and severing of the LHRH signal transduction mechanism. With the modifications of GnRH decapeptide by amino acid substitution or chemical alterations, GnRH agonists like Leuprolide, Goserelin, Triptorelin, and Histrelin are now commercially available in a variety of forms [13]. With a perspective to lower testosterone levels and attain the most outstanding efficiency of achieving medical castration, Triptorelin is the most puissant LHRH agonist, followed by Leuprolide and Goserelin [14]. The adverse effects of these medications include initial flare, loss of libido, erectile dysfunction, anemia, and muscle fatigue, as well as musculoskeletal, hematologic, and cardiovascular events. Therefore, before initiation of treatment, patients should be familiarized with the expected side effects and the efficient and effective methods of managing them, including lifestyle modifications and complementary medications [15].

ANTIANDROGENS

Anti-androgens stunt cancer growth by binding the androgen receptors at the cellular level. They are also called androgen receptor antagonists [16]. A few commercially used antiandrogens include Flutamide, Bicalutamide, and Nilutamide. To circumvent androgen flare, it is preferred to administer antiandrogen in the first month of using an LHRH agonist. Androgen synthesis is achieved 90 to 95% by the Testes and 10% by the Adrenals. To attain maximum androgen blockage, the LHRH agonist should be affixed with antiandrogens to reduce the testosterone produced by the Testes and Adrenals to castrate levels [17].

LUTEINIZING HORMONE-RELEASING HORMONE (LHRH) ANTAGONISTS

LHRH antagonists, commonly referred to as gonadotropin-releasing hormone [GnRH] antagonists, can perform medical castration. Without causing a hot flare aftereffect, LHRH antagonists function by blocking the antigen receptors and inhibiting the production of gonadotropins and testosterone [18]. Abarelix was the first LHRH antagonist medication licensed by the US Food and Drug Administration (FDA) for metastatic prostate cancer with a higher rate of medical castration in 2004; nonetheless, it has been associated with a systemic allergic reaction that could be fatal. However, during a clinical trial, more than 2,000 patients received medical castration with the synthetic peptide Degarelix in 2008 without experiencing any immediate or delayed systemic adverse reactions [18,19].

Due to prostate cancer's resistance to ADT and the high likelihood of transmuting into castrate-resistant prostate cancer (CRPC), the therapy landscape for metastatic prostate cancer has significantly changed over time [19]. Drugs including Docetaxel, Abiraterone, Enzalutamide, and Apalutamide are used in this therapeutic environment, and some trials have shown improvements.

CASTRATION-RESISTANT PROSTATE CANCER

In 80 to 90% of instances of metastatic prostate cancer, the early effect of ADT often involves a sharp reduction in serum prostate-specific antigen (PSA). Castrate-resistant prostate cancer, on the other hand, develops in some prostate cancer patients who become resistant to hormonal therapy [20]. The Food and Drug Administration (FDA) has approved the supracastration hormonal therapies abiraterone and enzalutamide for treating CRPC in patients who have never received chemotherapy and those who have developed a resistance to it, respectively. Enzalutamide and abiraterone functionally prevent testosterone from binding to the androgen receptor [21,22]. Further, it is interesting to note that a current effective therapy for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer is Lutetium-177 (^{177}Lu)–PSMA-617 (Radioligand therapy) based on the recent VISION and Therap trials as compared with cabazitaxel [23, 24]; approved by FDA and sold under the brand name Pluvicto.

When prostate cancer spreads while receiving androgen deprivation therapy (ADT), it is said to be "castration-resistant". It is characterized by an ongoing rise in prostate-specific antigen (PSA) blood levels. Prostate cancer hormonal therapy can be avoided using a variety of methods. The primary tumor escape strategies involved in castrate-resistant prostate cancer were histologic transformation, cancer stem cell target modification, and bypass signaling, which included partial obstruction of AR-ligand signaling, AR amplification, AR mutations, aberrant AR co-regulator activities, and AR splice-variant expression [25].

BYPASS SIGNALING PATHWAYS

Androgen receptors can increase autonomously by going through signaling pathways. This takes place through the transactivation of AR, which is prompted by cytokines, growth factors, and neurotransmitters [26]. Below, a number of the signaling bypass's mechanisms are covered.

ANDROGEN RECEPTOR AMPLIFICATION

Castration-resistant cells that express such a high level of AR can withstand low levels of androgen during ADT and give rise to recurrent clonal proliferation. About 30% of all patients who progressed to CRPC had X-chromosome polysomy and X-q12 gene amplification, but not in hormone-naive tissues. Additionally, having more than one copy of the AR gene increases the expression of the AR mRNA and protein, which promotes the growth of new cancers [27].

The prostate is an androgen-dependent organ, and prostate cancer is an androgen-dependent condition. Androgen mediates androgen actions through the androgen receptor (AR), a hormone-activated transcription factor. The direct control of gene expression is brought about by the binding of androgens (testosterone and dihydrotestosterone) to the androgen receptor [27,28]. The spontaneous or chromosomal rearrangements mutation of androgen receptors makes them resistant to receptor-targeted treatment. For example, H874Y and T877A mutations have been found in the circulating cell-free DNA of patients who no longer respond to abiraterone therapy. When antiandrogen therapy was terminated, Suzuki et al. found that expression of this mutation in CRPC patients was associated with a considerable drop in prostate-specific antigen. Similar to this, the AR antagonists ARN-509 and enzalutamide become agonists when the AR-LBD missense mutation (F876L) is present [28].

SPLICE VARIANTS

AR splice variants are significant for CRPC patients who have developed resistance to enzalutamide and abiraterone, which happens as primary resistance in 20 to 40% of cases and as subsequent resistance in virtually all instances despite initial remission. AR splice variants produce a different form of the AR protein that has a working N-terminal domain and a partially or fully functional DNA binding domain (DBD) that can interact with DNA and AR co-receptors but lacks the C-terminal ligand-binding domain (LBD). The majority of AR-V7 is expressed in CRPC metastases, while AR-V3 and AR-V9 may also co-express [27,28].

ALTERATION OF AR CO-REGULATORS

Co-regulators are protein complexes that bind to AR to control translational activity, they comprise coactivators, inhibitors, and chromatin remodelers. Maximum regulation of androgen activity depends on the balance of AR-mediated transcription, whereas an imbalance may cause higher or lower AR activity [28,29]. Less antagonist activity brought on by anti-androgen medication is observed in CRPC due to an increase in AR coactivator and a decrease in AR co-inhibitor. CHD1 is a tumor-suppressor gene that prevents the development of prostate tumors. The CHD1 gene loss in CRPC increases the transcriptional activities that fuel prostate carcinogenesis. Another coactivator for prostate cancer growth is homeobox B13 or HOXB13. HOXB13 mRNA is overexpressed in prostate cancer, and further research has demonstrated that HOXB13 mediates the AR-V7 oncogenic activity. However, in the presence of androgen co-inhibitors, Src protein kinase gene silencing activity most effectively prevents AR inhibitors from leading to CRPC [29].

HISTOLOGIC TRANSFORMATION AND CANCER STEM CELLS

A small percentage of individuals with advanced prostate cancer experience histologic change into tiny neuroendocrine cells as a mechanism of treatment resistance. Neuroendocrine cells are not frequently present in normal prostatic tissue as secretory cells. In prostate adenocarcinomas, immunohistochemistry can identify various neuroendocrine cells [29,30]. Squamous cell carcinoma (SCC), an uncommon and aggressive cancer, can also develop from prostate adenocarcinoma. Tumor cells that have the capacity for self-renewal, differentiation, and proliferation are known as cancer stem cells (CSCs). Tumors are resistant to therapy form due to cancer cells adapting to the therapeutic environment [30].

CANCER HORMONAL THERAPY CLINICAL TRIALS

Clinical trials are human research initiatives designed to improve medical treatment and quality of life for people with a particular ailment. New interventions and treatments are researched, and their effects on human participants are assessed in clinical trials. For example, the TAX and SWOG studies [31] used Docetaxel as the first cytotoxic agent to establish survival improvements for the treatment of CRPC, which was in 2004. These trials also altered a new generation of likely clinical studies that contrast the outcome of a post-docetaxel context. The CHAARTED, STAMPEDE, and GETUG-AFU 15 phase III trials, as well as the development of several more trials, were sparked by the question of whether Docetaxel could offer an early survival benefit when taken in metastatic hormone-sensitive prostate cancer. The characteristics of these trials are shown in table 1.

Table 1. CLINICAL TRIALS SHOWING OVERALL SURVIVAL OUTCOMES

SIDE EFFECTS	Fatigue, sensory neuropathy, infection		Neutropenic fever, nausea, vomiting, and Cardiovascular events	Febrile neutropenia and fatigue	Symptomatic skeletal events	Abnormalities in mineralo-corticoid and liver function test.	Endocrine disorders, febrile neutropenia		Rash, hypothyroidism, and fracture	Grade 3 hypertension and hypokalemia
P-VALUE	0.009 (D3P)	0.36 (D1P)	0.02	< 0.001	< 0.001	0.01	0.006	0.022	< 0.001	< 0.001
HR (95% CL)	0.76 (0.62-0.94)	0.91 (0.75-1.11)	0.80 (0.67-0.97)	0.61 (0.47-0.80)	0.63 (0.52-0.76)	0.75 (0.61-0.93)	0.70 (0.56-0.88)	0.82 (0.69-0.97)	0.28 (0.23-0.35)	0.62 (0.51-0.76)
CON. ARM	16.5	16.5	15.6	44	76% at 3 years	27.2	71	71	16.2	34.7
EXP. ARM	18.9	17.4	17.5	57.6	83% at 3 years	ND	81	76	40.5	ND
TARGET	AR	AR, Tubulin and Microtubules	AR, Tubulin and Microtubules	Bcl-2 phosphorylation	CYP17	CYP17	AR	AR, Bone marrow	AR	CYP17

INTERVENTIONS	Docetaxel + Prednisone versus Mitoxantrone + Prednisone	Docetaxel + Estramustine versus Mitoxantrone + Prednisone	ADT + Docetaxel versus ADT	ADT + Abiraterone + Prednisone versus ADT	Abiraterone + Prednisone versus Placebo + Prednisone	ADT + Docetaxel + Zoledronic acid versus ADT	Apalutamide + ADT versus Placebo + ADT	ADT + Abiraterone + Prednisone versus ADT + Placebo
N	1006	770	790	1917	1088	2962	1207	1199
NCT NO.	ND	NCT00004001	NCT00309985	NCT00268476	NCT00887198	NCT00268476	NCT01946204	NCT01715285
STUDY	TAX 327 [31]	SWOG 99 – 16 [32]	CHARTE D [33]	STAMPEDE [34]	COU-AA 302 [34]	STAMPEDE [35]	SPARTAN [33]	LATITUDE [31]
CLINICAL STATE	mHRPC	mAIPC	mHSPC	mHSPC	mCRPC	SmHSPC	nmCRPC	mHSPC

SIDE EFFECTS	Chills, fever, and headache	Fatigue and hypertension	Mineralocorticoid excess	Anemia, seizures	Anemia	Febrile neutropenia	Fatigue and Musculoskeletal events	Anemia, abdominal pain
---------------------	-----------------------------	--------------------------	--------------------------	------------------	--------	---------------------	------------------------------------	------------------------

P-VALUE	0.03	0.022	< 0.001	< 0.001	< 0.001	< 0.001	0.001	< 0.001
HR (95% CL)	0.78 (0.61-0.98)	0.82 (0.69-0.97)	0.65 (0.54-0.77)	0.63 (0.53-0.75)	0.70 (0.58-0.83)	0.70 (0.59-0.83)	0.80 (0.61-0.89)	0.39 (0.30-0.50)
CO N. AR M	21.7	71	10.9	13.6	11.3	12.7	56.3	19
EX P.A R M	25.8	76	14.8	18.4	14.9	15.1	67	ND
TA R G E T	PAP	AR	CYP17	AR	Bone metastasis	Tubulin	AR	AR
INT ER VE NTI ON S	Sipuleucel -t versus Placebo	Enzalutamide versus Placebo	Abiraterone + Prednisone versus Placebo + Prednisone	Enzalutamide versus Placebo	Alpharadin versus Placebo	Cabazitaxel + Prednisone versus Mitoxantrone + Prednisone	Enzalutamide + ADT versus Placebo + ADT	ADT + Enzalutamide versus Placebo + ADT
N	512	1717	1195	1199	921	755	1401	1150
NC T NO.	NCT00065442	NCT01212991	NCT00638690	NCT00974311	NCT00699751	NCT00417079	NCT02003924	NCT02677896
ST U D Y	IMPACT [33]	PREVAIL [35]	COU-AA 301 [35]	AFFIRM [31]	ALSYMPCA [31]	TROPIC [31]	PROSPER [34]	ARCHES [35]
CLI NI CAL ST AT E	mCRPC	mCRPC	Post-docetaxel mCRPC	CRPC	mCRPC	mCRPC	nmCRPC	mHSPC

SIDE EFFECTS	Fatigue, seizures	Rashes	Fatigue	Rash, hyperglycemia, high aminotransferase, and diarrhea
PVALUE	0.002	0.005	< 0.001	0.043 (not sig. at 0.01)
HR (95% CL)	0.67 (0.52-0.86)	0.67 (0.51-0.89)	0.68 (0.57-0.80)	0.84 (0.71-0.99)
CONVERSION	72% at 3 years	73.5% at 2 years	ND	16.6
EXPLANATION	80% at 3 years	82.4% at 2 years	32.5% increase than con. arm	19.2
TARGET	AR	AR	AR	AR
INTERVENTIONS	Enzalutamide versus LHRHA	Apalutamide + ADT versus ADT + Placebo	Darolutamide + ADT + Docetaxel versus Placebo + ADT + Docetaxel	Ipatasertib + Abiraterone + Prednisone versus Placebo + Abiraterone + prednisone
N	1125	1052	1306	1097
NCIT NO.	NCT02446405	NCT02489318	NCT02799602	NCT03072238
STUDY	ENZAMET [36]	TITAN [34]	ARASENS [33]	IPATential150 [33]
CLINICAL STAGE	mHSPC	mHSPC	mHSPC	mCRPC

Abbreviations: n, sample size; NCT no, National Clinical Trial number; CI, confidence interval; HR, Hazard Ratio; Exp. Arm, Experimental Arm; Con. Arm, Control Arm; mCRPC, metastatic Castration-Resistant Prostate Cancer; ADT, androgen deprivation therapy; CI, confidence interval; nmCRPC, non-metastatic Castration-Resistant Prostate Cancer; mHSPC, metastatic hormone-sensitive prostate cancer; ND, not described; PAP, Prostatic Acid Phosphatase; mHRPC, Metastatic Hormone-Refractory Prostate Cancer; mAIPC, Metastatic Androgen-Independent Prostate Cancer; D3P, Docetaxel 3 × Weekly + Prednisone; DIP, Docetaxel 3 × Weekly + Prednisone;

ACTIVE CLINICAL TRIALS

The Clinical trial (ENZAMET) sponsored by the University of Sydney and registered under the identifier NCT02446405 is one of the ongoing trials being conducted. The Randomised Phase 3 Trial encompasses a cohort of 1125 participants. The primary objective is to evaluate the effectiveness of enzalutamide in comparison to a conventional non-steroidal antiandrogen (NSAA), when combined with a luteinizing hormone-releasing hormone analog (LHRHA) or surgical castration, as the initial course of androgen deprivation therapy (ADT) for recently diagnosed individuals with metastatic prostate cancer. The anticipated completion date for this comprehensive study is estimated to be December 2024.

Also, conducted under the study identifier NCT03821792, a Phase 2 clinical investigation is currently underway, focusing on ascertaining the efficacy of abiraterone acetate, prednisone, and apalutamide in the treatment of male patients afflicted with hormone-naïve metastatic prostate cancer (HNMPCa). The trial aims to evaluate the extent to which the aforementioned medications effectively counteract the progression of prostate cancer cells that are stimulated by androgen. Through the implementation of antihormone therapy, specifically abiraterone acetate and apalutamide, it is anticipated that the production of androgen within the body will be attenuated. M.D. Anderson Cancer Center serves as the sponsor for the study, with the National Cancer Institute (NCI) acting as a collaborative partner. The estimated date for primary completion of this trial, involving 60 participants, is October 2023.

Another trial, sponsored by AstraZeneca, aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of AZD5305 when administered alongside new hormonal agents (NHAs) in individuals diagnosed with Metastatic Prostate Cancer. Termed PETRANHA, this Multi-arm, Open-label Phase I/IIa Study encompasses the evaluation of AZD5305 in conjunction with new hormonal agents such as Enzalutamide, Abiraterone Acetate, and Darolutamide. Commencing on June 2, 2022, the study is expected to reach its primary completion by March 15, 2029, and involves the participation of 520 individuals. The study identifier for reference is NCT05367440.

CONCLUSION

Risk factors for prostate cancer include genetic mutation, advancing age, a positive family history, smoking, and ethnicity (mainly in black Americans). Prostate cancer is a multi-genetic disease that is a global health concern. The use of hormone therapy as a prostate cancer treatment option is underutilized, although several

hormone therapies can both treat and halt the progression of the disease. More choices for hormone therapy must be developed due to expanding understanding to contain further and eradicate prostate cancer globally.

REFERENCES

- [1] Daniyal, M., Siddiqui, Z.A., Akram, M., Asif, H.M., Sultana, S. and Khan, A., 2014. Epidemiology, etiology, diagnosis and treatment of prostate cancer. *Asian Pacific Journal of Cancer Prevention*, 15(22), pp.9575-9578.
- [2] Zuccolo L, Harris R, Gunnell D, Oliver S, Lane JA, Davis M, *et al.* Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. *Cancer Epidemiology Biomarkers & Prevention*. 2008 Sep;17(9):2325-36.
- [3] Testa U, Castelli G, Pelosi E. Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. *Medicines*. 2019 Jul 30;6(3):82.
- [4] Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, *et al.* Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 2005 Nov 1;60(11):1451-7.
- [5] Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. *International journal of impotence research*. 2009 Jan;21(1):9-23.
- [6] Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. *The Journal of urology*. 2005 Feb 1;173(2):533-6.
- [7] Khara M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, *et al.* Testosterone replacement therapy following radical prostatectomy. *The journal of sexual medicine*. 2009 Apr;6(4):1165-70.
- [8] Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. *European urology*. 2012 Nov 1;62(5):757-64.
- [9] Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. *European urology*. 2009 Feb 1;55(2):310-21.
- [10] Kim JW. Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. *Investigative and clinical urology*. 2020 May;61(3):242.
- [11] Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. *Reviews in urology*. 2007;9(Suppl 1):S3.
- [12] Lei JH, Liu LR, Wei Q, Yan SB, Song TR, Lin FS, *et al.* Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. *Scientific Reports*. 2015 Jan 12;5(1):7713.
- [13] Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. *Reviews in Urology*. 2005;7(Suppl 5):S3.
- [14] González Del Alba A, Méndez-Vidal MJ, Vazquez S, Castro E, Climent MA, Gallardo E, *et al.* SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). *Clinical and Translational Oncology*. 2021 May;23:969-79.
- [15] Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. *Reviews in urology*. 2012;14(1-2):1.

- [16] Rick FG, Block NL, Schally AV. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. *OncoTargets and therapy*. 2013 Apr 16;391-402.
- [17] Crawford ED, Hou AH. The role of LHRH antagonists in the treatment of prostate cancer. *Oncology*. 2009 Jun 1;23(7):626.
- [18] Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. *Nature clinical practice Urology*. 2009 Feb;6(2):76-85.
- [19] Crowley F, Sterpi M, Buckley C, Margetich L, Handa S, Dovey Z. A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer. *Research and Reports in Urology*. 2021 Jun 30:457-72.
- [20] Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene*. 2013 Dec;32(49):5501-11.
- [21] Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. *Nature Reviews Cancer*. 2015 Dec;15(12):701-11.
- [22] Rohith G. (2021). VISION trial: 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer. *Indian journal of urology : IJU : journal of the Urological Society of India*, 37(4), 372–373.
- [23] Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., *et al.* TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2021). [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. *Lancet (London, England)*, 397(10276), 797–804.
- [24] Imamura Y, Sadar MD. Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinic. *International Journal of Urology*. 2016 Aug;23(8):654-65.
- [25] Joseph JD, Lu N, Qian J, Sensintaffar J, Shao G, Brigham D, *et al.* A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509AR F876L Confers Enzalutamide and ARN-509 Resistance. *Cancer discovery*. 2013 Sep 1;3(9):1020-9.
- [26] Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis CJ, De Souza P, *et al.* Abiraterone in metastatic prostate cancer without previous chemotherapy. *New England Journal of Medicine*. 2013 Jan 10;368(2):138-48.
- [27] Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, *et al.* Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. *The Journal of clinical investigation*. 2019 Jan 3;129(1):192-208.
- [28] Kallio HM, Hieta R, Latonen L, Brofeldt A, Annala M, Kivinummi K, *et al.* Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. *British journal of cancer*. 2018 Aug 1;119(3):347-56.
- [29] Ehsani M, David FO, Baniahmad A. Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. *Cancers*. 2021 Mar 26;13(7):1534.
- [30] Senapati D, Kumari S, Heemers HV. Androgen receptor co-regulation in prostate cancer. *Asian Journal of Urology*. 2020 Jul 1;7(3):219-32.
- [31] Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. *Clinical Cancer Research*. 2009 May 15;15(10):3540-9.

- [32] Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, *et al.* Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. *Journal of Clinical Oncology*. 2018 Apr 4;36(11):1080.
- [33] James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, *et al.* Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *The Lancet*. 2016 Mar 19;387(10024):1163-77.
- [34] Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, *et al.* Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *New England Journal of Medicine*. 2010 Jul 29;363(5):411-22.
- [35] De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, *et al.* Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *The Lancet*. 2010 Oct 2;376(9747):1147-54.
- [36] Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, *et al.* Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. *New England Journal of Medicine*. 2018 Jun 28;378(26):2465-74.
- [37] Armstrong AJ, Szmulewitz RZ, Petrylak DP, Villers A, Azad A, Alcaraz A, *et al.* Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.
- [38] Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, *et al.* Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. *New England Journal of Medicine*. 2022 Mar 24;386(12):1132-42.